Form 4: Generation Bio Director Jason Rhodes Granted 30,000 Stock Options

Generation Bio Co. Director Jason P. Rhodes was granted 30,000 stock options with an exercise price of $0.3874, vesting by June 2026.

Summary

• Jason P. Rhodes, a Director of Generation Bio Co. (GBIO), was granted 30,000 stock options on June 4, 2025.
• The stock options have an exercise price of $0.3874 per share.
• The shares underlying the option will fully vest on the earlier of June 4, 2026, and the date of Generation Bio's 2026 annual meeting of stockholders.
• The options have an expiration date of June 3, 2035.
• Following this transaction, Mr. Rhodes beneficially owns 30,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive, as the document reports a routine insider equity grant, which aligns director interests with shareholders and is a standard compensation practice, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term value creation.
• This is a standard form of equity compensation for board members, indicating routine corporate governance practices.

Future Outlook

The granted stock options are set to fully vest on the earlier of June 4, 2026, or the date of Generation Bio's 2026 annual meeting of stockholders, and will expire on June 3, 2035.

Management Comments

• Jason P. Rhodes disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any, due to his obligation to transfer economic benefit to Atlas Venture Life Science Advisors, LLC.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages to align leadership incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation mechanism across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The specific exercise price and vesting schedule are typical for equity grants designed to incentivize long-term commitment and performance.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive for aligning management and board interests with shareholder value creation, potentially leading to better long-term performance.

Next Steps

• The granted stock options will vest on the earlier of June 4, 2026, or the date of Generation Bio's 2026 annual meeting of stockholders.
• Jason P. Rhodes may exercise the options at any time after vesting and before the expiration date of June 3, 2035.

Key Dates

Keywords

Generation Bio, GBIO, Stock Option, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership